“NuvOx Therapeutics Receives FDA Fast Track Designation to NanO₂™ for the Treatment of Acute Ischemic Stroke.
NuvOx Therapeutics, Inc. (“NuvOx Therapeutics”, “NuvOx”, or the “Company”) today announces that its wholly owned subsidiary, NuvOx Pharma LLC, has been granted Fast Track designation for NanO₂™ by the U.S. Food and Drug Administration (“FDA”) for the treatment of adult patients presenting with acute ischemic stroke (“AIS”).
Acute ischemic stroke remains a leading cause of death and long-term disability worldwide. Despite advances in mechanical thrombectomy and thrombolytic therapy, many patients experience irreversible brain injury due to inadequate oxygen delivery to ischemic tissue before blood flow can be restored.
Fast Track designation is intended to facilitate the development and expedite the review of therapies that have the potential to treat serious conditions and fill an unmet medical need. The designation provides opportunities for more frequent interactions with the FDA, eligibility for rolling review of marketing applications, and the potential for Priority Review if relevant criteria are met. The Fast Track designation further strengthens NuvOx Therapeutics’ regulatory strategy as the Company advances its clinical development program. NanO₂ is currently being evaluated in clinical studies designed to assess its ability to improve neurological outcomes when administered alongside standard stroke therapies.”